Product Program year 2025 Source: CMS Open Payments

Zolgensma

Drug Neurology

NDC 71894-120-02

Open in the dashboard

General payments

$257,132

306 payments

Research payments

$3,775,369

284 payments

Through program year 2025, $257,132 in general payments and $3,775,369 in research payments were reported against Zolgensma (Neurology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2025 General $102,004 170
2025 Research $1,304,213 179
2024 General $155,128 136
2024 Research $2,471,156 105

Breakdown

Who paid General payments · program years 2024–2025
  1. Novartis Pharmaceuticals Corporation $149,018 282 payments
  2. AveXis $72,167 15 payments
  3. Novartis Pharma AG $35,948 9 payments
Top recipients General payments · program year 2025
  1. Richard Finkel Neurology with Special Qualifications in Child Neurology · Memphis, TN $32,286 32% · 5 payments
  2. Lauren Elman Neurology · Philadelphia, PA $6,745 7% · 5 payments
  3. Oscar Mayer Pediatric Pulmonology · Philadelphia, PA $5,820 6% · 5 payments
  4. Julie Parsons Neurology with Special Qualifications in Child Neurology · Aurora, CO $5,024 5% · 5 payments
  5. John Day Neuromuscular Medicine · Stanford, CA $5,012 5% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Neurology with Special Qualifications in Child Neurology Psychiatry & Neurology $60,249 62% · 44 practitioners
  2. Neurology Psychiatry & Neurology $14,660 15% · 17 practitioners
  3. Neuromuscular Medicine Psychiatry & Neurology $10,276 11% · 10 practitioners
  4. Pediatric Pulmonology Pediatrics $5,820 6% · 1 practitioner
  5. Pediatrics $3,776 4% · 4 practitioners

The top 5 of 23 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Tennessee $37,091 36% · 4 recipients
  2. Pennsylvania $16,985 17% · 6 recipients
  3. California $11,218 11% · 16 recipients
  4. Utah $6,500 6% · 2 recipients
  5. New York $5,836 6% · 5 recipients

The top 5 of 32 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

306 general · 284 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record